Shares of Theseus Pharmaceuticals took a significant hit on Friday following the company's announcement that it would be discontinuing the development of THE-630 for patients with gastrointestinal stromal tumors. The decision to terminate development came after the company discovered two dose-limiting toxicities associated with hand-foot skin reaction. As a result, Theseus … [Read more...] about Theseus Pharmaceuticals Terminates Development of THE-630
Footer
